{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:49:37Z","timestamp":1767192577739,"version":"3.45.0"},"reference-count":31,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2016,8,1]]},"DOI":"10.1188\/16.cjon.405-410","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T11:51:29Z","timestamp":1469101889000},"page":"405-410","source":"Crossref","is-referenced-by-count":14,"title":["Update on New Therapies With Immune Checkpoint Inhibitors"],"prefix":"10.1188","volume":"20","author":[{"given":"Jennifer","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Steele-Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"1","unstructured":"American Cancer Society. (2015). What is cancer immunotherapy? Retrieved from http:\/\/www.cancer.org\/treatment\/treatmentsandsideeffects\/treatmenttypes\/immunotherapy\/immunotherapy-what-is-immunotherapy"},{"key":"2","unstructured":"Bisanz, A. (2011). Diarrhea and its multiple causes [Video transcript]. Retrieved from http:\/\/www.mdanderson.org\/ transcripts\/POE-Diarrhea-Multiple-Causes-Bisanz.htm"},{"key":"3","unstructured":"Bristol-Myers Squibb. (2015). Yervoy\u00ae (ipilimumab) [Package insert]. Retrieved from http:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf"},{"key":"4","unstructured":"Bristol-Myers Squibb. (2016). Opdivo\u00ae (nivolumab) [Package insert]. Retrieved from http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"5","unstructured":"ClinicalTrials.gov. (2015a). A study to compare BMS-936558 to the physician\u2019s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy (CheckMate 037). Retrieved from https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01721746"},{"key":"6","unstructured":"ClinicalTrials.gov. (2015b). Study of BMS-936558 (nivolumab) compared to docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) (CheckMate 017). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01642004"},{"key":"7","unstructured":"ClinicalTrials.gov. (2015c). Study of nivolumab (BMS-936558) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer who have received at least 2 prior systemic regimens. Retrieved from https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01721759?term=NCT01721759"},{"key":"8","unstructured":"ClinicalTrials.gov. (2015d). Study of pembrolizumab (MK-3475) versus chemotherapy in participants with advanced melanoma (P08719\/KEYNOTE-002). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01704287"},{"key":"9","doi-asserted-by":"crossref","unstructured":"DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., & Jacks, T. (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482, 405\u2013409. doi:10.1038\/nature10803","DOI":"10.1038\/nature10803"},{"key":"10","unstructured":"Elgert, K.D. (2009). Immunology: Understanding the immune system (2nd ed.). Hoboken, NJ: John Wiley and Sons."},{"key":"11","unstructured":"Giaccone, G., & Soria, J. (Eds.). (2008). Targeted therapies in oncology (2nd ed.). Boca Raton, FL: CRC Press."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hanahan, D., & Weinberg, R.A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646\u2013674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ito, F., & Chang, A.E. (2013). Cancer immunotherapy: Current status and future directions. Surgical Oncology Clinics of North America, 22, 765\u2013783","DOI":"10.1016\/j.soc.2013.06.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kannan, R., Madden, K., & Andrews, S. (2014). Primer on immuno-oncology and immune response. Clinical Journal of Oncology Nursing, 18, 311\u2013317. doi:10.1188\/14.CJON.311-317","DOI":"10.1188\/14.CJON.311-317"},{"key":"15","unstructured":"Lartigue, J. (2012, October 31). Targeting PD-1: Immune checkpoint strategy finds new spot to arrest cancer. Retrieved from http:\/\/www.onclive.com\/publications\/Oncology-live\/2012\/October-2012\/Targeting-PD-1-Immune-Checkpoint-Strategy -Finds-New-Spot-to-Arrest-Cancer"},{"key":"16","unstructured":"McCarthy, E.F. (2006). The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthopaedic Journal, 26, 154\u2013158"},{"key":"17","unstructured":"Mendes, E. (2014, June 16). Immunotherapy: Disrupting the cancer treatment world. Retrieved from http:\/\/www.cancer .org\/research\/acsresearchupdates\/more\/immunotherapy -disrupting-the-cancer-treatment-world"},{"key":"18","unstructured":"Merck and Co., Inc. (2015). Keytruda\u00ae (pembrolizumab) [Package insert]. Retrieved from http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf"},{"key":"19","unstructured":"Murphy, K. (2014). Janeway\u2019s immunobiology (8th ed.). Abingdon, UK: Garland Science."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Oxnard, G.R., Morris, M.J., Hodi, F.S., Baker, L.H., Kris, M.G., Venook, A.P., & Schwartz, L.H. (2012). When progressive disease does not mean treatment failure: Reconsidering the criteria for progression. Journal of the National Cancer Institute, 104, 1534\u20131541. doi:10.1093\/jnci\/djs353","DOI":"10.1093\/jnci\/djs353"},{"key":"21","unstructured":"Pazdur, R. (2013, July 3). FDA approval for ipilimumab. Retrieved from http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-ipilimumab"},{"key":"22","unstructured":"Polovich, M., Olsen, M., & LeFebvre, K. (2014). Chemotherapy and biotherapy guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Postma, T., & Heimans, J.J. (2000). Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology, 11, 509\u2013513.","DOI":"10.1023\/A:1008345613594"},{"key":"24","unstructured":"Postow, M., & Wolchok, J. (2016). Toxicities associated with checkpoint inhibitor immunotherapy. Retrieved from http:\/\/www.uptodate.com\/contents\/toxicities-associated-with -checkpoint-inhibitor-immunotherapy?"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Prendergast, G.C. (2008). Immune escape as a fundamental trait of cancer: Focus on IDO. Oncogene, 27, 3889\u20133900.","DOI":"10.1038\/onc.2008.35"},{"key":"26","unstructured":"Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., . . . Wolchok, J.D. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33, 1889\u20131894. doi:10.1200\/JCO .2014.56.2736"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Tarhini, A. (2013). Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica, 2013, 857519. doi:10.1155\/2013\/857519","DOI":"10.1155\/2013\/857519"},{"key":"28","unstructured":"U.S. Food and Drug Administration. (2016). Hematology\/oncology (cancer) approvals and safety notifications. Retrieved from http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ ApprovedDrugs\/ucm279174.htm"},{"key":"29","unstructured":"U.S. National Library of Medicine. (2016). Severity grading in drug induced liver injury. Retrieved from http:\/\/livertox.nih .gov\/Severity.html"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Vajdic, C.M., & van Leeuwen, M.T. (2009). Cancer incidence and risk factors after solid organ transplantation. International Journal of Cancer, 125, 1747\u20131754.","DOI":"10.1002\/ijc.24439"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Weber, J.S., K\u00e4hler, K., & Hauschild, A. (2012). Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 30, 2691\u20132697.","DOI":"10.1200\/JCO.2012.41.6750"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/20\/4\/update-new-therapies-immune-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:35Z","timestamp":1763754755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/20\/4\/update-new-therapies-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.cjon.405-410","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}